A study on the MSH2 in non-small-cell lung cancer (NSCLC) suggested that although the gene was not mutated, 29% of NSCLC cases were found with decline in epigenetic expression of MSH2 [11]. This evidence concerns the gene MSH2 and non-small cell lung carcinoma.